ArticleFood science & nutrition2025
Exocarpium Citri Grandis Attenuates Lipopolysaccharide-Induced Acute Liver Injury Through Suppression of Inflammatory, Apoptotic, Oxidative, and Ferroptotic Pathways.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Protective effects of Astragaloside IV on various liver diseases: From chemistry to herbal medicines (Review).International journal of molecular medicine · 2026Review
- Dual Roles of Natural Products in Regulating Ferroptosis in Acute and Chronic Liver Diseases: A Review.Oxidative medicine and cellular longevity · 2026Review
- Rhynchophylline attenuates porcine pseudorabies virus-induced astrocyte injury by modulating oxidative stress, inflammation, and metabolic abnormalities.Frontiers in pharmacology · 2026Article
- Glycyrrhizin preparations in liver diseases: a narrative review of mechanisms and therapeutic potential.Frontiers in pharmacology · 2026Review
- Natural products in treating sepsis-associated lung and liver injuries by mediating ferroptosis, current progress, and future perspective.Frontiers in pharmacology · 2026Review
- Exocarpium Citri Grandis Attenuates Lipopolysaccharide-Induced Acute Liver Injury Through Suppression of Inflammatory, Apoptotic, Oxidative, and Ferroptotic Pathways.Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to elucidate the therapeutic mechanisms of Exocarpium Citri Grandis (ECG) against lipopolysaccharide (LPS)-induced acute liver injury (ALI) using an integrated approach combining network pharmacology and experimental validation. The chemical profile of ECG was characterized via UHPLC-Q-Exactive MS. Male C57BL/6J mice were employed to establish an LPS-induced ALI murine model for evaluating hepatoprotective effects of ECG. Serum AST/ALT levels, histopathology changes, and inflammatory, apoptotic, oxidative, and ferroptotic markers were analyzed. Additionally, network pharmacology was used to identify the targets and pathways of ECG, while molecular docking validated interactions between bioactive compounds and key regulatory molecules. ECG treatment significantly reduced serum AST/ALT levels (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.